Table 1.
Summary of cases available in the literature that used venetoclax in BPDCN
| Study | N | Median age | Median previous lines | Added treatments | Type of response | Max. duration of response | Follow-up |
|---|---|---|---|---|---|---|---|
| Grushchak et al. Medicine (2017)[8] | 1 | 65 | 2 | No | CR | >10 months | 10 months |
| Montero et al. Cancer Discov. (2017)[7] | 2 | 76,5 | 3 | No | PR | 4 weeks | Until death |
| DiNardo et al. Am J Hematol. (2018)[5] | 2 | 74,5 | 3 | Yes, NR but probably HMA or LDAC | CR/PR | NR | NR |
| Agha et al. N Engl J Med. (2018)[10] | 1 | 62 | 4 | No | CR | >9 months | 9 months |
| Beziat et al. Leuk Res. (2019)[11] | 1 | 77 | 1 | No | PR | 1 month | NR |
| Piccini et al. Ann Hematol. (2020)[12] | 1 | 64 | 2 | Azacitidine | CR | >11 months | 11 months |
| Samhouri et al. J Oncol Pharm Pract. (2020)[13] | 1 | 79 | 1 | Azacitidine | PR | >6 months | 6 months |
| Albiol et al. J Med Case Rep. (2021) | 1 | 54 | 4 plus intrathecal therapy | No | PR | 3 months | Until death |
CR complete response, PR partial response, NR not reported, HMA hypomethylating agent, LDAC low-dose ara-C